New endocrine therapy has a better effect on BRCA mutation carriers compared with non-carriers in the mCRPC population, and PCa populations with BRCA1 or BRCA2 mutations could benefit from abiraterone or enzalutamide treatment (16). The gene discussed is BRCA1; the disease is posterior cortical atrophy.